Skip to main
LGVN
LGVN logo

Longeveron (LGVN) Stock Forecast & Price Target

Longeveron (LGVN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Longeveron Inc. is poised for significant growth due to its innovative stem cell therapy, Lomecel-B, which has demonstrated remarkable safety and efficacy in clinical trials, particularly in delivering 100% five-year transplant-free survival in Hypoplastic Left Heart Syndrome patients. The company's promising pipeline includes indications for Alzheimer's disease and aging-related frailty, reflecting its commitment to addressing critical unmet medical needs in aging-related health challenges. A revised discounted cash flow analysis suggests a substantial upside potential in the stock price, indicating strong market confidence in the company’s future success and potential FDA approvals.

Bears say

Longeveron Inc. has experienced a significant decline of approximately 56% year-to-date, primarily attributed to concerns surrounding the safety profile of Lomecel-B in clinical trials, particularly for Hypoplastic Left Heart Syndrome patients. Additionally, the ongoing ELPIS II study may fail to demonstrate positive efficacy, which could further hinder the company’s progression in the competitive biotech landscape. The potential for delays in securing necessary funding, regulatory approval, and achieving effective market penetration adds another layer of financial uncertainty that negatively impacts investor confidence.

Longeveron (LGVN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Longeveron and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Longeveron (LGVN) Forecast

Analysts have given Longeveron (LGVN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Longeveron (LGVN) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Longeveron (LGVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.